3. Results
INFLAMMATION, ADVERSE EVENT
The first participant was screened 16 August 2021, and the third intervention sequence ended on 11 October 2021. A total of 24 subjects were enrolled, randomized, and had at least one investigational product intake. Two subjects dropped out, which resulted in 22 subjects completing all periods and sequences, reflecting a high adherence to study procedures and product compliance. The reasons for participants dropping out were that one person had an adverse event after the first period (inflammation of the knee), which was not related to the product, and the other withdrew from the study without further explanation. All 24 participants were included in the analysis set both for efficacy and safety.The population, with mean age 34 years, was healthy (